Bluejay Diagnostics (BJDX) Net Cash Flow (QoQ) (2021 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Bluejay Diagnostics | 572,394.44 | -3.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -165.61% |
| Dec 31, 2025 | 265.81% |
| Sep 30, 2025 | -202.55% |
| Jun 30, 2025 | 211.90% |
| Mar 31, 2025 | 18.43% |
| Dec 31, 2024 | 36.86% |
| Sep 30, 2024 | -142.66% |
| Jun 30, 2024 | 1,092.36% |
| Mar 31, 2024 | 115.78% |
| Dec 31, 2023 | -12,121.65% |
| Sep 30, 2023 | 98.60% |
| Jun 30, 2023 | 49.55% |
| Mar 31, 2023 | -4.73% |
| Dec 31, 2022 | -55.05% |
| Sep 30, 2022 | -15.16% |
| Jun 30, 2022 | 7.34% |
| Mar 31, 2022 | -111.51% |
| Dec 31, 2021 | 23,874.00% |
| Sep 30, 2021 | -103.27% |
| Jun 30, 2021 | 424.61% |
| Mar 31, 2021 | -179.01% |